2026-10-19T00:23:44Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/126572026-10-18T21:13:25Zopenairedrivercom_ebyu_10000col_ebyu_10001Formulation and characterization studies of inclusion complexes of voriconazole for possible ocular applicationBaşaran, EbruAykaç, KadirYenilmez, EvrimBüyükköroğlu, GülayTunali, YağmurDemirel, Müzeyyenantifungal activityinclusion complexeslyophilizationVoriconazole2-Hydroxypropyl-beta-cyclodextrinAnimalsbeta-CyclodextrinsMiceMycosesSolubility2 hydroxypropyl beta cyclodextrinalpha cyclodextrinbeta cyclodextrincyclodextrin derivativegamma cyclodextrinmethyl beta cyclodextrinbeta cyclodextrin derivativemycosis3T3 cell lineanimal cellanimal experimentanimal modelArticleAspergillusbroth dilutionCandida albicansCandida glabrataCandida parapsilosiscomplex formationcontrolled studyIn our study, Voriconazole (VOR) was selected as an active agent to be used for the treatment of ocular fungal infections. To overcome low aqueous solubility of VOR, inclusion complexes with α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), γ-cyclodextrin (γ-CD), hydroxypropyl-cyclodextrin (HP-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD) hydroxypropyl-γ-cyclodextrin (HP-γ-CD), methyl-β-cyclodextrin (M-β-CD) and sulfabutylether-β-cyclodextrin (SBE-β-CD) were formulated. Characterization studies revealed that inclusion complexes were formulated successfully with the lyophilization method. Aqueous solubility of VOR was enhanced up to 86 fold with the formation of the inclusion complexes. MTT analyses results revealed the safety of the complexes on 3T3 mouse fibroblast cell lines while Microbroth Dilution Method revealed the remarkable antifungal activities of the complexes. Analyses results revealed that inclusion complexes will overcome the poor ocular bioavailability of VOR resulting inefficient treatment of severe ocular fungal infections. © 2022 Informa UK Limited, trading as Taylor & Francis Group.Taylor and Francis Ltd.2022Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12657https://doi.org/10.1080/10837450.2022.20376351083-7450enPharmaceutical Development and Technologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12657